A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis.
Type: Article
Collaboration
Year: 2021
Writers
Jimenez-Morales, A; Chalice, R; Olive, S; Prades, M.; Blanch, C.
Magazine
Title: CLINICAL RHEUMATOLOGY